Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Simon K. Lo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1263-0400; OpenAlex author ID A5061068832, A5106131023, A5106132156, A5112478953, A5113315957, A5150993405. Sources: OpenAlex.

Their work

Papers
29 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 6 papers · 2023: 3 papers · 2024: 5 papers · 2025: 5 papers · 2026: 1 paper

Papers 29

  1. Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization. Co-author DOI 10.1002/pon.70601↗
  2. Selective removal of proteins and microvesicles ex vivo from blood of pancreatic cancer patients using bioengineered adsorption filters. Co-author DOI 10.1016/j.canlet.2025.217546↗
  3. Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directed care. Co-author DOI 10.1016/j.hpb.2025.07.012↗
  4. A Clinical Laboratory Improvement Amendments/College of American Pathologists-Compliant Noninvasive Laboratory-Developed Test for Early Detection of Pancreatic… Co-author DOI 10.1016/j.jmoldx.2024.10.001↗
  5. Circulating tumor cell and oncosome subtypes in portal and peripheral venous circulations may be used for diagnosis and prognostication of pancreatic cancer. Co-author DOI 10.1038/s41698-025-01165-4↗
  6. Significantly higher incidence of circulating fatty objects in portal blood samples compared to peripheral blood samples in patients with pancreatic ductal ade… Co-author DOI 10.3389/fonc.2025.1611872↗
  7. Accuracy of Clinical Staging in Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jama.2024.16332↗
  8. Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. Last author DOI 10.1038/s41698-024-00521-0↗
  9. Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy. Co-author DOI 10.1038/s44276-024-00069-3↗
  10. Ascites Is a Poor Prognostic Factor in Advanced Pancreatic Adenocarcinoma and May Be Undertreated: A Prospective Cohort Study. Co-author DOI 10.14309/ctg.0000000000000719↗
  11. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analy… Co-author DOI 10.3390/cancers16050971↗
  12. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001-2018. Co-author DOI 10.1053/j.gastro.2023.01.022↗
  13. Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical … First author DOI 10.1097/mpa.0000000000002236↗
  14. Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000-2018. Co-author DOI 10.3390/cancers15030870↗
  15. Incidence of Pancreatic Cancer by Age and Sex in the US From 2000 to 2018-Reply. First author DOI 10.1001/jama.2022.2315↗
  16. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. Co-author DOI 10.1016/j.pan.2021.09.015↗
  17. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-19401-3↗
  18. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-23619-6↗
  19. Chemical Exchange Saturation Transfer for Pancreatic Ductal Adenocarcinoma Evaluation. Co-author DOI 10.1097/mpa.0000000000002059↗
  20. Multitasking dynamic contrast enhanced magnetic resonance imaging can accurately differentiate chronic pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.1007134↗
  21. Incidence of Pancreatic Cancer by Age and Sex in the US, 2000-2018. Last author DOI 10.1001/jama.2021.18859↗
  22. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. Co-author DOI 10.1002/jcsm.12799↗
  23. Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mrm.28167↗
  24. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unres… Co-author DOI 10.4103/eus.eus_44_19↗
  25. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2018.12.060↗
  26. Comparison of endoscopic ultrasound guided fine needle aspiration and PET/CT in preoperative diagnosis of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2017.04.008↗
  27. Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1200/po.17.00016↗
  28. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Co-author DOI 10.3389/fphys.2014.00088↗
  29. Endoscopic palliation of pancreatic cancer. Co-author DOI 10.1016/j.gtc.2011.12.005↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Srinivas Gaddam · 16 shared papers, 2020–2026 · strength 2.92
  2. Stephen Jacob Pandol · 16 shared papers, 2014–2025 · strength 2.69
  3. Andrew Eugene Hendifar · 18 shared papers, 2014–2026 · strength 2.56
  4. Arsen Osipov · 13 shared papers, 2019–2026 · strength 2.14
  5. Nicholas N. Nissen · 13 shared papers, 2014–2025 · strength 1.88
  6. Jun Gong · 9 shared papers, 2021–2026 · strength 1.50
  7. Brent K. Larson · 5 shared papers, 2022–2025 · strength 0.89
  8. Stephanie N. Shishido · 4 shared papers, 2024–2025 · strength 0.85
  9. Peter Kühn · 4 shared papers, 2024–2025 · strength 0.85
  10. Debiao Li · 6 shared papers, 2020–2024 · strength 0.84
  11. Rabindra R. Watson · 4 shared papers, 2023–2025 · strength 0.75
  12. Ruoxiang Wang · 3 shared papers, 2024–2025 · strength 0.65
  13. Abrahm Levi · 3 shared papers, 2024–2026 · strength 0.64
  14. Yazan Abboud · 4 shared papers, 2021–2024 · strength 0.62
  15. Jamil S. Samaan · 3 shared papers, 2021–2023 · strength 0.43
  16. Cristina Rosa Ferrone · 2 shared papers, 2024–2025 · strength 0.43
  17. Natalie Moshayedi · 3 shared papers, 2022 · strength 0.41
  18. Gillian K. Gresham · 3 shared papers, 2021–2022 · strength 0.38
  19. Richard Tuli · 5 shared papers, 2014–2020 · strength 0.38
  20. Zhaoyang Fan · 3 shared papers, 2020–2022 · strength 0.37
  21. Lixia Wang · 3 shared papers, 2020–2022 · strength 0.37
  22. Nan Wang · 3 shared papers, 2020–2022 · strength 0.37
  23. Anthony G Christodoulou · 3 shared papers, 2020–2022 · strength 0.37
  24. Veronica Placencio-Hickok · 3 shared papers, 2019–2022 · strength 0.33
  25. Silvana Debernardi · 1 shared paper, 2025 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.